These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31132182)

  • 1. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
    Ständer S; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1742-1746. PubMed ID: 31132182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
    Simpson EL; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Ständer S; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
    Acta Derm Venereol; 2019 Jul; 99(9):756-761. PubMed ID: 30896779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
    Eichenfield LF; Yosipovitch G; Stein Gold LF; Kalabis M; Zang C; Vlahos B; Sanders P; Myers DE; Bushmakin AG; Cappelleri JC; Olivadoti M; Paller AS
    Pediatr Dermatol; 2020 Nov; 37(6):1030-1037. PubMed ID: 32981097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis.
    Stein Gold LF; Tom WL; Shi V; Sanders P; Zang C; Vlahos B; Cha A
    Dermatitis; 2024; 35(1):84-91. PubMed ID: 38206678
    [No Abstract]   [Full Text] [Related]  

  • 6. Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.
    Simpson EL; Paller AS; Boguniewicz M; Eichenfield LF; Feldman SR; Silverberg JI; Chamlin SL; Zane LT
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):605-619. PubMed ID: 30345457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Among Treatment, Pruritus, Investigator's Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis.
    Simpson EL; Tom WL; Bushmakin AG; Cappelleri JC; Yosipovitch G; Ständer S; Luger T; Sanders P; Gerber RA; Myers DE
    Dermatol Ther (Heidelb); 2021 Apr; 11(2):587-598. PubMed ID: 33751495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
    Spergel JM; Blaiss MS; Lio P; Kessel A; Cantrell WC; Takiya L; Werth JL; O'Connell MA; Zang C; Cork MJ
    Allergy Asthma Proc; 2021 Sep; 42(5):425-431. PubMed ID: 34474712
    [No Abstract]   [Full Text] [Related]  

  • 10. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
    Bissonnette R; Pavel AB; Diaz A; Werth JL; Zang C; Vranic I; Purohit VS; Zielinski MA; Vlahos B; Estrada YD; Saint-Cyr Proulx E; Ports WC; Guttman-Yassky E
    J Allergy Clin Immunol; 2019 Nov; 144(5):1274-1289. PubMed ID: 31419544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
    Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
    J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies.
    Draelos ZD; Stein Gold LF; Murrell DF; Hughes MH; Zane LT
    J Drugs Dermatol; 2016 Feb; 15(2):172-6. PubMed ID: 26885784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
    Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
    Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
    Silverberg JI; Tallman AM; Ports WC; Gerber RA; Tan H; Zielinski MA
    Acta Derm Venereol; 2020 Jun; 100(13):adv00170. PubMed ID: 32318744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
    Fujita K; Yagi M; Moriwaki S; Yoshida M; Graham D
    J Dermatol; 2021 Nov; 48(11):1640-1651. PubMed ID: 34435694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
    Stein Gold LF; Takiya L; Zang C; Sanders P; Feldman SR
    J Drugs Dermatol; 2020 Jun; 19(6):619-624. PubMed ID: 32574023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF; Gebauer K; Spelman L; Zane LT
    J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.
    Ryan Wolf J; Chen A; Wieser J; Johnson B; Baughman L; Lee G; Pope E; Franco A; Love T; Beck LA
    J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1364-1372. PubMed ID: 38357778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
    Luger TA; Hebert AA; Zaenglein AL; Silverberg JI; Tan H; Ports WC; Zielinski MA
    Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
    Callender VD; Alexis AF; Stein Gold LF; Lebwohl MG; Paller AS; Desai SR; Tan H; Ports WC; Zielinski MA; Tallman AM
    Am J Clin Dermatol; 2019 Oct; 20(5):711-723. PubMed ID: 31264114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.